Key Highlights

  • Amdocs (NASDAQ:DOX) dropped 28.55% to USD 44.61 once its fiscal 2027 Revenue outlook called for a 14.3% to 17.9% decline, while a contract disagreement with its biggest customer weighed on sentiment.
  • Fidelity National Information Services (NYSE:FIS) fell 21.93% to USD 30.44 after a reduced 2026 forecast and a buyback pause, despite third quarter revenue climbing 27% to USD 3,454 million.
  • Unum Group (NYSE:UNM) lost 18.93%, falling to USD 73.80, after reporting a USD 419.7 million net loss in the third quarter and a disability ratio that reached 70.6%, compared with 61.3% a year earlier.
  • The 21.00% decline at Modine Manufacturing and the 18.14% fall at UroGen Pharma both came after solid growth paired with slimmer margins or weaker guidance, among them a 470 basis point hit to Data Centers margins and a reduction in JELMYTO guidance.

Amdocs (NASDAQ:DOX): Off 28.55% Over a Fiscal 2027 Forecast and Client Conflict

Amdocs (NASDAQ:DOX) traded at USD 44.61, a 28.55% decline in intraday action on November 4, 2026, which backs out to a prior close near USD 62.44 and a USD 17.83 drop (calculated). Pre-market the shares had been off roughly 40%, so part of that loss was clawed back. The trigger was results for the fourth fiscal quarter and the full year 2026, published November 3. Fiscal 2026 revenue reached USD 4,697 million, up 3.6%, and non-GAAP diluted EPS came to USD 7.41, up 6.0%. Looking to fiscal 2027, the company expects reported sales to shrink by 14.3% to 17.9%, and non-GAAP EPS to drop 26% to 30%. The report notes that both parties have issued notices claiming material breach against its largest customer, and the outlook allows for termination by either side. Twelve-month Backlog stood at USD 3.50 billion. Amdocs (NASDAQ:DOX) has not disclosed how much revenue that customer represents, so any exposure figure is an outside guess, and arbitration may add legal expense.

Fidelity National Information Services (NYSE:FIS): Off 21.93% on a Reduced Forecast

Fidelity National Information Services (NYSE:FIS) traded at USD 30.44 on November 4, 2026, down 21.93%, implying a previous close of USD 38.99 and a USD 8.55 decline (calculated). The company reported third quarter figures on November 4, and investors reacted to the forward view rather than the quarter itself. Revenue came in at USD 3,454 million, up 27%, with adjusted EPS of USD 1.61 versus USD 1.51, while GAAP diluted EPS was USD 0.69. The 2026 forecast calls for revenue of USD 13,445 million to USD 13,505 million and adjusted EPS of USD 5.82 to USD 5.89. Published coverage called the guidance a reduction and said the finance chief is departing; that item is relayed from coverage and absent from the portion of the release we examined. Fidelity National Information Services (NYSE:FIS) bought back just USD 21 million of stock during the quarter and paused repurchases temporarily to accelerate Debt reduction, with bigger Buybacks expected once gross Leverage gets near 2.8 times. Dividend payments continue.

Unum Group (NYSE:UNM): Off 18.93% Following a Q3 Deficit and Higher Claims

Unum Group (NYSE:UNM) changed hands at USD 73.80 in regular trading on November 4, 2026, down 18.93%, which works back to a previous close of USD 91.03 and a USD 17.23 decline (calculated). The release dated November 3 showed a GAAP net loss of USD 419.7 million, or USD 2.65 per diluted share, reflecting an Investment hit before tax of USD 853.0 million, of which USD 833.5 million tied to the Fortitude Re long-term care Reinsurance deal. Adjusted Operating Income landed at USD 2.20 per share versus a restated USD 2.81 a year earlier, following a change in how the company defines it. Excluding notable items, the disability benefit ratio climbed to 70.6% from 61.3%, which management linked to more long-term disability filings alongside behavioral health costs. The 2026 outlook for adjusted operating income moved up to USD 8.30 to USD 8.50 per share, though roughly USD 0.33 of that comes from a beneficial one-time item. Unum Group (NYSE:UNM) offered no 2027 guidance, and each point of benefit ratio comes straight out of margin.

Modine Manufacturing (NYSE:MOD): Off 21.00% as Data Center Profitability Eased

Modine Manufacturing (NYSE:MOD) traded at USD 99.10 on November 4, 2026, down 21.00%, implying a previous close of USD 125.44 and a USD 26.34 drop (calculated). Second quarter fiscal 2027 results were issued on November 3. Net sales reached USD 994.4 million, up 35%, adjusted EPS came to USD 1.35 versus USD 1.06, and adjusted EBITDA climbed 31% to USD 136.2 million. GAAP diluted EPS dropped to USD 0.56 from USD 0.83, chiefly due to a USD 29.5 million tax charge linked to the Performance Technologies spin-off. Data Centers sales climbed 95% to USD 439.7 million, yet segment gross Margin slid 470 basis points to 19.7%, while Commercial HVAC margin eased 140 basis points to 23.1%. The fiscal 2027 outlook for continuing operations projects net sales of USD 3.1 billion to USD 3.2 billion. Published coverage said KeyCorp lowered its target to USD 225 from USD 280, a reported view rather than a company statement. Modine Manufacturing (NYSE:MOD) demonstrates that growth can still find buyers even when margins shrink.

UroGen Pharma (NASDAQ:URGN): Off 18.14% Following a JELMYTO Outlook Reduction

UroGen Pharma (NASDAQ:URGN) traded at USD 28.16 intraday on November 4, 2026, down 18.14%, which works back to a previous close of USD 34.40 and a USD 6.24 decline (calculated). Timing lines up with the company release issued at 8:00 a.m. ET on November 4, 2026. Third quarter total revenue came to USD 89.0 million, with ZUSDURI supplying USD 68.0 million, up 35% sequentially. JELMYTO sales reached USD 21.0 million, and management trimmed 2026 JELMYTO guidance to about USD 90 million from a prior USD 97 million to USD 101 million. Published coverage characterized total revenue as lighter than analyst expectations, though the consensus number was not verified. The net loss shrank to USD 1.5 million from USD 33.3 million, yet cash and marketable securities declined to USD 90.5 million from USD 120.5 million at December 31, 2025, and the Balance Sheet reflects a shareholders' deficit. UroGen Pharma (NASDAQ:URGN) holds a PDUFA review target of June 14, 2027 for UGN-103. The shares stay exposed to how well the launch goes.

Where Things Stand

Amdocs (NASDAQ:DOX) suffered the steepest Earnings decline at 28.55%. The shared pattern is that the quarter held up while the outlook, margins or balance sheet fell short. Fidelity National Information Services (NYSE:FIS) halted buybacks. Unum Group (NYSE:UNM) posted a net loss alongside higher disability claims. Modine Manufacturing (NYSE:MOD) watched Data Centers margins contract. UroGen Pharma (NASDAQ:URGN) lowered a product forecast. Investors are resetting expectations rather than just reacting to results, and intraday moves can flip or deepen as analysts revise models and companies submit their 10-Qs.